Provochonline Solution.
Coming Soon
Provochonline
Provochonline Solution Logo
INTRODUCING

Provocholine® Inhalation Solution

Methapharm Respiratory is excited to introduce our new Provocholine product, the only FDA approved ready-to-use methacholine chloride solution for the methacholine challenge test. This sterile solution is used to assess airway hyperresponsiveness, a key clinical feature of asthma. Provocholine Solution is indicated in adults and children 5 years of age and older when asthma suspected.

Same globally trusted product in a new convenient formulation.

Provocholine Solution packaging.

Ready-to-Use Premixed Kit

For the Methacholine Challenge Test

Sterile

No mixing, no wait time

Stored at room temperature

24 months BUD

Single patient kit – no waste

Colour-coded concentrations avoids errors

Dosing protocol recommended in ATS/ERS guidelines (quadrupling)

Two women, a doctor and patient, reviewing information on a computer screen.

Ready-to-Use Premixed Kit

For the Methacholine Challenge Test

Sterile

No mixing, no wait time

Stored at room temperature

24 months BUD

Single patient kit – no waste

Colour-coded concentrations avoids errors

Dosing protocol recommended in ATS/ERS guidelines (quadrupling)

Provocholine Solution packaging.

Product Information

Product Insert

Provocholine Solution Prescribing Information

Reimbursement

Provochonline Reimbursement Information
WARNING: SEVERE BRONCHOCONSTRICTION

Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV1 < 60% predicted or adults with FEV1 < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended. Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapidacting inhaled bronchodilator agent (β-agonist). If baseline spirometry is not performed or is measured inaccurately, the initial FEV1 may be underestimated. In this situation, decreases in FEV1 may not be detected after administration of escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increased risk for excessive bronchoconstriction [See Warnings and Precautions- Section 5 of the Product Monograph].